4.4 Article

Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis

期刊

ARTHRITIS CARE & RESEARCH
卷 73, 期 4, 页码 593-602

出版社

WILEY
DOI: 10.1002/acr.24139

关键词

-

资金

  1. Pfizer
  2. NIHR Oxford Biomedical Research Centre
  3. Clinician Scientist award of the National Medical Research Council, Singapore [NMRC/CSA-INV/0022/2017]
  4. Jerome L. Greene Foundation Scholar award
  5. National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH [P30-AR-070254]
  6. NIHR Clinician Scientist award

向作者/读者索取更多资源

HAQ DI, SF-12 PCS, and PsAID-FC are valid measures of physical function for PsA, with PsAID-FC being potentially a more sensitive option to measure PsA-specific physical function.
Objective We evaluated the psychometric properties of 3 patient-reported outcome measures to assess the physical function in psoriatic arthritis (PsA). Methods Data were available for the Health Assessment Questionnaire disability index (HAQ DI), the 12-item Short Form instrument physical component summary (SF-12 PCS), and the Psoriatic Arthritis Impact of Disease instrument functional capacity score (PsAID-FC). Data came from a longitudinal study in 14 countries of consecutive adults with definite PsA with >= 2 years of duration. The score distribution, construct validity, responsiveness, and thresholds of meaning of the patient-reported outcome measures were evaluated. Results At baseline, 414 subjects (52% male) were analyzed. The mean +/- SD age was 52.4 +/- 12.5 years and duration of illness was 10.9 +/- 8.1 years. Ceiling effects were noted in 31% and 21% of patients for HAQ DI and PsAID-FC, respectively; floor effects were minimal. All 3 patient-reported outcome measures met a priori hypotheses for construct validity. After a median follow-up of 4.1 (interquartile range 2.7) months in 350 patients, 27%, 54%, and 18% of patients reported themselves improved, not changed, and worsened, respectively. Change scores were statistically different for groups for worsening versus no-change for all patient-reported outcome measures. PsAID-FC was more sensitive to change than the other 2 patient-reported outcome measures. Comparing groups with worsening condition to no-change, the standardized response mean square ratios were HAQ DI 29.9, SF-12 PCS 16.7, and PsAID-FC 40.1. Conclusion HAQ DI, SF-12 PCS, and PsAID-FC are valid measures of physical function for PsA. PsAID-FC, a single question, performed similarly to the other patient-reported outcome measures and may be an additional option to measure PsA-specific physical function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing

Lihi Eder, Ruth Croxford, Aaron M. Drucker, Arielle Mendel, Bindee Kuriya, Zahi Touma, Sindhu R. Johnson, Richard Cook, Sasha Bernatsky, Nigil Haroon, Jessica Widdifield

Summary: Compared with the general population, patients with immune-mediated inflammatory diseases (IMIDs) were more likely to be tested for SARS-CoV-2, but the infection rate was similar. The odds of SARS-CoV-2 infection varied across different IMID subgroups.

ARTHRITIS CARE & RESEARCH (2023)

Letter Rheumatology

Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson et al

Ricardo J. O. Ferreira, Paco M. J. Welsing, Johannes W. G. Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M. Machado, Desiree van der Heijde, Jose A. P. Da Silva

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2238 Patients With Psoriatic Arthritis

Ana-Maria Orbai, William Tillett, Suzanne Grieb, Steve Peterson, Elizabeth A. Holdsworth, Nicola Booth, Soumya D. Chakravarty, Laure Gossec

Summary: This study described the flares of psoriatic arthritis (PsA) and their impact on patient-reported outcomes (PROs). Results showed that flare status was associated with worse quality of life, work impairment, and disability. The study suggests that PsA flares should be regularly assessed and managed in clinical care.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Laura C. Coates, Christopher T. Ritchlin, Laure Gossec, Philip S. Helliwell, Proton Rahman, Alexa P. Kollmeier, Xie L. Xu, May Shawi, Chetan S. Karyekar, Christine Contre, Wim Noel, Shihong Sheng, Yanli Wang, Stephen Xu, Philip J. Mease

Summary: The study evaluated the efficacy of guselkumab for treating active psoriatic arthritis. The results showed that guselkumab provided sustained benefits over 1 year and was found to be an effective therapy for diverse manifestations of psoriatic arthritis.

RHEUMATOLOGY (2023)

Review Rheumatology

Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations

Ying-Ying Leung, Tatiana V. Korotaeva, Liliana Candia, Susanne Juhl Pedersen, Wilson Bautista Molano, Eric M. Ruderman, Radjesh Bisoendial, Rodolfo Perez-Alamino, Wendy Olsder, Burkhard Moeller, Simeon Grazio, Tania Gudu, Girish M. Mody, Carlos Pineda, Helena Raffayova, Sherry Rohekar, Claudia Goldenstein-Schainberg, Sergio R. Gutierrez Urena, Julio Cesar Casasola Vargas, Bhowmik Meghnathi, Roopa Prasad, Pascal Richette, Jose Roberto S. Miranda, Nikolas Malliotis, Ulla Lindqvist, David Simon, Amara Ezeonyeli, Enrique R. Soriano, Oliver FitzGerald

Summary: The objective of this study was to provide evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of PsA for the revised 2021 GRAPPA treatment recommendations. Evidence was derived from new RCTs and recommendations were made for different patient groups based on their treatment history and response. Different classes of therapeutic options were strongly recommended for different patient groups.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe

Jessica A. Walsh, Alexis Ogdie, Kaleb Michaud, Steven Peterson, Elizabeth A. Holdsworth, Chetan S. Karyekar, Nicola Booth, Chloe Middleton-Dalby, Soumya D. Chakravarty, Natalie Dennis, Laure Gossec

Summary: This study found that key manifestations of psoriatic arthritis (PsA) have varying impacts on quality of life, physical function, and work disability. These manifestations include peripheral arthritis, psoriasis, axial involvement, enthesitis, and dactylitis. The results show that these symptoms are associated with poorer general and disease-specific quality of life, physical function, and work disability.

JOINT BONE SPINE (2023)

Review Rheumatology

Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review the 2021 GRAPPA Treatment Recommendations

Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher, M. Elaine Husni

Summary: This study summarizes the efficacy and safety of advanced therapies for psoriatic arthritis in patients with related conditions, including Crohn's disease, ulcerative colitis, and noninfectious uveitis. The tumor necrosis factor inhibitor (TNFi) class appears to be effective and safe, while interleukin 12/23 inhibitors (IL-12/23i) show efficacy in Crohn's disease and ulcerative colitis. However, caution should be exercised when using interleukin 17 inhibitors (IL-17i) in patients with psoriatic arthritis at high risk of inflammatory bowel disease.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Patient-defined flares and disease activity worsening in 222 patients with psoriatic arthritis from 14 countries

Marlene Sousa, Ennio Lubrano, Josef S. Smolen, Clemence Gorlier, Maarten de Wit, Laura C. Coates, Umut Kalyoncu, Adeline Ruyssen-Witrand, Ying-Ying Leung, Rossana Scrivo, Juan D. Canete, Penelope Palominos, Sandra Meisalu, Andra Balanescu, Uta Kiltz, Sibel Zehra Aydin, Inna Gaydukova, Emmanuelle Dernis, Bruno Fautrel, Ana-Maria Orbai, Laure Gossec

Summary: This study aimed to explore patient-defined flares in psoriatic arthritis (PsA) and compare them to an increase in disease activity in psoriatic arthritis (DAPSA). The validity of a patient-reported flare question was also analyzed. The results showed that patient-reported flares were associated with disease activity and symptoms, and there was moderate agreement between patient and physician definitions of worsening.

JOINT BONE SPINE (2023)

Article Rheumatology

Social cognitive theory to improve symptom appraisal and help-seeking among patients with autoimmune rheumatic diseases: A qualitative study

Ling Xiang, Sungwon Yoon, Andrea H. L. Low, Ying Ying Leung, Warren Fong, Tang Ching Lau, Dow Rhoon Koh, Julian Thumboo

Summary: This study explores the applicability of social cognitive theory (SCT) in improving symptom appraisal and help-seeking among patients with autoimmune rheumatic diseases (ARDs). Semi-structured interviews were conducted with 33 ARD patients and the transcripts were coded using SCT as the framework. The study found that behavioral capacity and self-efficacy were lacking in symptom interpretation, leading to delayed help-seeking. Possible approaches to address this include education to improve behavioral capacity and self-efficacy and enhance expectations, observational learning, reinforcements, and reciprocal determinism.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Medicine, General & Internal

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

Alexander Ooms, Hussein Al-Mossawi, Louise Bennett, Mimi Bogale, Paul Bowness, Anne Francis, Carl Goodyear, Bruce W. Kirkham, Sylvine Lalnunhlimi, Iain B. Mcinnes, Duncan Richards, Stefan Siebert, Leonie S. Taams, Aysin Tulunay Virlan, Nicole Yager, Laura C. Coates

Summary: Psoriatic arthritis (PsA) affects a significant number of people in the UK and requires treatment with biologics. This study aims to investigate whether baseline Th17 levels can predict response to IL-17A or TNF inhibitors in PsA patients, and whether additional factors can refine the prediction model. The findings from this study may have implications for treatment guidelines in PsA.

BMJ OPEN (2023)

Review Rheumatology

Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

Oliver FitzGerald, Frank Behrens, Anne Barton, Heidi Bertheussen, Bruno Boutouyrie-Dumont, Laura Coates, Owen Davies, Maarten de Wit, Filippo Fagni, Carl S. Goodyear, Robert Gurke, Lisa Hahnefeld, Christine Huppertz, Vassilios Ioannidis, Mark Ibberson, Arnon Katz, Maximilian Klippstein, Michaela Koehm, Shimon Korish, Sina Mackay, David A. Martin, Denis O'Sullivan, Khadijah Patel, Stefan Rueping, Georg Schett, Klaus Scholich, Jochen M. Schwenk, Stefan Siebert, David Simon, Arani Vivekanantham, Stephen R. Pennington, HIPPOCRATES Consortium

Summary: Achieving good outcomes for Psoriatic Arthritis (PsA) patients is challenging due to late diagnosis, diverse clinical presentation, and failure to control inflammatory features. To address these unmet needs, the HIPPOCRATES program, a collaboration between academic centers, pharmaceutical industry partners, and patient-representative organizations, aims to improve the diagnosis, management, and treatment of PsA in a five-year Innovative Medicines Initiative (IMI) initiative. The program's ambitious work and challenges are outlined, with the goal of ultimately improving short-term and long-term outcomes for PsA patients.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2023)

Article Rheumatology

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study

Magnus B. Petersen, Rebekka L. Hansen, Alexander Egeberg, Tanja S. Jorgensen, Joseph Frank Merola, Laura C. Coates, Lars Erik Kristensen

Summary: Comorbidities did not affect treatment persistence or clinical response rates in patients with PsA treated with first-line IL-17i. However, comorbidities were associated with increased baseline disease activity and frequency of depression and/or anxiety.

RHEUMATOLOGY ADVANCES IN PRACTICE (2023)

Correction Rheumatology

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study (vol 25, 150, 2023)

Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert

ARTHRITIS RESEARCH & THERAPY (2023)

暂无数据